Published in J Zhejiang Univ Sci B on July 01, 2005
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine (2014) 1.02
HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. PLoS One (2013) 0.88
HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms. J Virol (2014) 0.85
tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. J Virol (2013) 0.79
Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications. PLoS One (2014) 0.77
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem (1999) 2.81
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A (1993) 1.93
Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol (1998) 1.52
Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J Immunol (1998) 1.31
Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol (1994) 1.29
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Tat and the HIV-1 promoter. Curr Opin Cell Biol (1993) 1.15
Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem (1998) 1.13
An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.10
Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. J Immunol (1999) 0.99
Tat-neutralizing antibodies in vaccinated macaques. J Virol (2003) 0.94
Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. J Gastroenterol Hepatol (2012) 1.72
Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol (2003) 1.56
HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. J Hepatol (2009) 1.49
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Effects of promyelocytic leukemia protein on virus-host balance. J Virol (2002) 1.28
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol (2007) 1.20
Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol (2009) 1.17
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine (2007) 1.13
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One (2012) 1.08
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology (2009) 1.02
Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J Med Virol (2002) 1.01
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99
HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology (2007) 0.97
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
Gene expression in primate liver during viral hemorrhagic fever. Virol J (2009) 0.97
Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One (2012) 0.97
The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol (2013) 0.96
The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus. J Virol (2005) 0.92
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine (2010) 0.90
Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J Med Virol (2004) 0.88
Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antiviral Res (2011) 0.88
Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes (2006) 0.88
Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro. J Virol (2012) 0.86
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J (2013) 0.86
Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate. PLoS Negl Trop Dis (2013) 0.85
Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem Inst Oswaldo Cruz (2009) 0.85
Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus. Blood (2009) 0.84
The features of reserpine-induced gastric mucosal lesions. Acta Pharmacol Sin (2010) 0.83
[Efficacy of lamivudine monotherapy and combination therapy with adefovir dipivoxil for patients with hepatitis B virus-related decompensated cirrhosis]. Zhonghua Gan Zang Bing Za Zhi (2011) 0.79
Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine (2012) 0.79
Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine (2006) 0.78
Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. J Virol (2013) 0.76
[Distribution of projection neurons of the superior olivary complex in the auditory brainstem in cats]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2008) 0.75
[Detection of serum total IgE, phadiatop and eosinophil cationic protein in patients with silicosis]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi (2012) 0.75
[Effect of HIV Tat protein on CCR5 expression in monocytes and infection with monocyte-tropic HIV strains]. Zhejiang Da Xue Xue Bao Yi Xue Ban (2004) 0.75
[Lipopolysaccharide (LPS) increases tumor necrosis factor-alpha related apoptosis induced-ligand (TRAIL) in macrophages killing HepG2 cells]. Zhonghua Gan Zang Bing Za Zhi (2005) 0.75